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Abstract  
Endothelin induced signaling pathways can affect blood pressure and vascular tone, but the 
influence of endothelins on tumor cells is also significant. We have detected elevated 
endothelin-1 secretion from TIMAP (TGF-β inhibited membrane associated protein) depleted 
vascular endothelial cells. The autocrine signaling activated by the elevated endothelin-1 level 
through the ETB receptors evoked an angiogenic-like phenotype, the cells assumed an 
elongated morphology, and enhanced tube formation and wound healing abilities. The 
depleted protein, TIMAP, is a highly specific and abundant protein in the endothel al cells, 
and it is a regulatory/targeting subunit for the catalytic subunit of protein phosphatase 1 
(PP1c). Protein-protein interaction between the TIMAP-PP1c complex and the endothelin 
converting enzyme-1 (ECE-1) was detected, the latter of which is a transmembrane protein 
that produces the biologically active 21-amino acid form of endothelin-1 from proendothelin. 
The results indicate that silencing of TIMAP induces a reduction in TIMAP-PP1c activity 
connected to ECE-1. This leads to an increase in the amount of ECE-1 protein in the plasma 
membrane and a consequent increase in endothelin-1 secretion. Similarly, activation of PKC, 
the kinase responsible for ECE-1 phosphorylation  increased ECE-1 protein level in the 
membrane fraction of the endothelial cells. The elevated ECE-1 level was mitigated in time in 
normal cells, but was clearly preserved in TIMAP-depleted cells. Overall, our results indicate 
that PKC-phosphorylated ECE-1 is a TIMAP-PP1c substrate and this phosphatase complex 
has an important role in endothelin-1 production of EC through the regulation of ECE-1 
activity. 
 
 
Keywords: protein phosphatase 1, TIMAP, endothelial cells, endothelin-1, endothelin 
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1. Introduction 
Vascular endothelial cells (EC) respond to physical and chemical signals by production of a 
wide range of factors, which regulate vascular tone, cellular adhesion, smooth muscle cell 
proliferation, and vessel wall inflammation. Structural changes in the pulmonary vasculature, 
disordered EC proliferation, andan altered production of endothelial vasoactive mediators 
(NO, prostacyclin, endothelin-1, serotonin, and thromboxane) has been recognized in patients 
with hypertension, coronary artery disease, chronic heart failure or preeclampsia.  
Endothelins are a family of peptides, which comprises of endothelin-1 (ET-1), endothelin-2 
(ET-2) and endothelin-3 (ET-3), each consisting of 21 amino acids. The predominant isoform 
in the vasculature is ET-1, one of the most potent vasoconstrictors (Masaki, 1998), produced 
primarily by vascular EC. Initially an inactive, large precursor form, prepro-ET-1 is produced 
(Kawanabe and Nauli, 2011), which is converted to pro-ET-1 after removal of a signal 
sequence. The formation of mature ET-1 requires a proteolytic cleavage catalyzed by one of 
the endothelin converting enzymes (ECEs) (Matsuoka et al., 1996, Meidan et al., 2005). Four 
isoforms of ECE-1 have been identified, all encoded by the same gene but under the control 
of different promoter regions (Meidan et al., 2005). ECE-1c isoform is the most dominant and 
therefore, it is the main physiological regulator of ET-1 production. PKC mediated 
phosphorylation of ECE-1c promotes its trafficking to the cell surface and increases its 
activity (Jafri and Ergul, 2006, Kuruppu et al., 2010).  
Elevated level of ET-1 has been detected in several cardiovascular diseases, such as 
atherosclerosis, heart failure or primary pulmonary hypertension (Lerman et al., 1991, Pacher 
et al., 1996, Stewart et al., 1991, Agapitov and Haynes, 2002), and it has been suggested as a 
potential indicator of endothelial dysfunction (Stewart et al., 1991). ET-1 acts both on 
endothelial- and smooth muscle cells of the pulmonary arteries (Boscoe et al., 2000). ET-1 
evolves its biological effects through activation of receptors belonging to the superfamily of 
G-protein coupled receptors, ETA and ETB. ETA receptors are found in smooth muscle cells, 
whereas ETB receptors found on both endothelial- and smooth muscle cells (White et al., 
1993, Avedanian et al., 2010). ET-1 can also play an important role in tumor growth and 
survival through regulated sprouting of new vessels into the tumor and surrounding tissues 
(Dawas et al., 1999).  
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TGF-β inhibited membrane-associated protein (TIMAP) is a typical endothelial cell (EC) type 
member of the myosin phosphatase targeting (MYPT) family of the regulatory subunits of 
protein phosphatase 1 (PP1) (Cao et al., 2002, Czikora et al., 2011, Csortos et al., 2008). 
Although TIMAP is highly expressed in EC, its importance is poorly recognized. Our group 
has shown a barrier protective role of TIMAP in human pulmonary artery endothelial cells 
(HPAEC) (Csortos et al., 2008). We demonstrated specific protein-protein interaction 
between TIMAP and the β isoform of the catalytic subunit of PP1 (PP1cβ) (Csortos et al., 
2008, Czikora et al., 2011), and identified a few substrates of the TIMAP-PP1c complex in 
pulmonary EC (Csortos et al., 2008, Czikora et al., 2011, Boratko et al., 2015). Regulation of 
PP1c activity in the TIMAP-PP1c complex is affected by PKA-primed GSK-3β-mediated 
phosphorylation of TIMAP (Li et al., 2007, Czikora et al., 2011, Boratko et al., 2013).  
To uncover novel cellular functions of TIMAP as targeting subunit of PP1, we initiated a 
search for new interacting partners and substrates of TIMAP-PP1c. In the present study, 
morphological changes and angiogenesis related proteome profiling of TIMAP depleted EC 
turned our attention toward the regulation of ECE-1 mediated ET-1 secretion from EC. We 
show results suggesting ECE-1 being a novel substrate of the TIMAP-PP1c complex. In the 
absence of TIMAP, the targeting of PP1c is insufficient, and eventually, dephosphorylation of 
ECE-1 becomes disabled.  This leads to sustained ECE-1 activity and increased secretion of 
ET-1, which evokes an angiogenic EC phenotype. 
2. Material and Methods 
2.1 Reagents 
Materials were obtained from the following vendors: paraformaldehyde, dimethylsulfoxide, 
bovine serum albumin, BQ788, Thiazolyl Blue Tetrazolium Bromide (MTT), Phorbol 12-
myristate 13-acetate, Gö6983, anti-actin antibody: Sigma (St Louis, MO); anti-rabbit IgG 
HRP-linked and anti-mouse IgG HRP-linked secondary antibodies, CD31(PECAM-1) 
antibody: Cell Signaling Technology, Inc. (Beverly, MA); anti-PP1 delta antibody, mouse 
anti-human endothelin-1 antibody: Upstate Biotechnology (Lake Placid, NY); anti-PPP1R16B 
antibody: Abgent Inc, (San Diego, CA); anti-lamin A/C (H-110) antibody: Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA); ECE-1 monoclonal antibody, anti-rat IgG HRP affinity 
purified antibody: R&D Systems, Inc., (Minneapolis, MN); TO-PRO-3 Iodide, Lipofectamine 
RNAiMax: Life Technologies (Carlsbad, CA); Alexa 488-conjugated secondary antibody and 
ProLong Gold Antifade medium: Molecular Probes (Eugene, OR);Protease Inhibitor Cocktail 
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Set III: EMD Biosciences (San Diego, CA); Substances for cell culturing were from PAA 
(Austria). All other chemicals were obtained from Sigma (St Louis, MO). 
2.2 Cell cultures 
Human pulmonary artery endothelial cells (HPAEC) (catalogue No: CC-2530) were obtained 
frozen at passage 3 (Lonza Group Ltd, Switzerland) and were cultured in EGM-2 Endothelial 
Cell Growth Medium-2 supplemented with 10% FBS and EGM-2 SingleQuots of Growth 
Factors. Cells were utilized at passages 4–6. Bovine pulmonary artery endothelial cells 
(BPAEC) (culture line-CCL 209) were obtained frozen at passage 8 (American Type Tissue 
Culture Collection, Rockville, MD), and were utilized at passages 15-20. Cells were 
maintained at 37°C in a humidified atmosphere of 5% CO2 and 95% air in MEM 
supplemented with 10% (v/v) heat inactivated fetal bovine serum, 1% sodium pyruvate, 
0.1mM MEM non-essential amino acids solution.   
2.3 siRNA silencing 
TIMAP (PPP1R16B) was silenced using 50 nM ON-TARGETplus SMARTpool siRNA (L-
004065-00-0005 HumanPPP1R16B, Dharmacon) in complex with Lipofectamine RNAiMAX 
reagent (Life Technologies) in serum-free medium. ON-TARGETplus siCONTROL non-
targeting pool (D-001810-10-01-05; Dharmacon) was used as an irrelevant control. After 6 h 
the medium was changed to complete medium. Cells were further incubated for 48 h. 
2.4 Immunofluorescence and microscopy  
Cells were grown on glass coverslips, washed once with 1X TBS and fixed with 3.7% 
paraformaldehyde in 1X TBS for 10 min at room temperature. Between each step, the cells 
were rinsed three times with 1X TBS. The cells were permeabilized with 0.5 % Triton X-100 
in TBS at RT for 15 min, blocked with 2% BSA in TBS for 30 min at RT, and incubated with 
primary, then with secondary antibodies diluted in blocking solution for 1 h at RT. Cover slips 
were rinsed and mounted in ProLong Gold Antifade medium. Confocal images were acquired 
with a Leica TCS SP8 confocal microscope using HC PL APO CS2 63x 1.40 NA oil 
immersion objective on an DMI6000 CS microscope at 25°C. Images were processed using 
LAS AF v3.1.3 software. Non-specific binding of the secondary antibodies was checked in 
control experiments (not shown). Light microscopy images were taken by Leica DM IL LED 
microscope using N Plan 5x/0.12 objective.  
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2.5 Immunoprecipitation 
Cells were grown in 100-mm tissue culture dishes, rinsed three times with 1x TBS and then 
collected and lysed with 600 μl of immunoprecipitation buffer (20 mM Tris HCl, pH 7.4, 150 
mM NaCl, 2 mM EDTA, 2 mM sodium vanadate, 1% Nonidet P-40) containing protease 
inhibitors. The lysates were centrifuged with 10,000 g for 15 min at 4°C. To avoid non-
specific binding, the supernatants were precleared with 50 μl of protein G Sepharose (GE 
Healthcare, Piscataway, NJ) at 4°C for 3 h with end-over-end rotation. Protein G Sepharose 
was removed by centrifugation at 4°C for 10 min, and the supernatant was incubated with the 
appropriate volume of antibody at 4°C for 1 h and then with 50 μl of fresh protein G 
Sepharose at 4°C overnight with gentle rotation. The resin was washed three times with 500 
μl of IP buffer and then resuspended in 150 μl of 1X SDS sample buffer, boiled, and 
microcentrifuged. The supernatant was further analyzed by Western blot. 
2.6 Subcellular fractionation 
Membrane fraction was isolated using Mem-PER Plus Membrane Protein Extraction Kit 
(Thermo Scientific, Inc.,Vantaa, Finland) according to the manufacturer’s protocol. The 
efficiency of fractionation was analyzed by immunoblotting using CD31 antibody as a 
membrane marker, and β-tubulin antibody as a cytoplasmic marker.  
2.7 Western blotting 
Protein samples were separated by 10-15% SDS-PAGE and transferred to 0.45 μm pore sized 
Hybond ECL Nitrocellulose Membrane (GE Healthcare, Piscataway, NJ). Membranes were 
blocked with TBST containing 5% low-fat milk for 1 h. Primary and secondary antibodies 
were diluted (according to the manufacturer’s recommendation) in TBST containing 1% BSA 
for 1 h or overnight. Western blots were imaged using an Alpha Innotech FluorChem® FC2 
Imager or Kodak Medical X-ray Developer. 
2.8 ECIS measurements 
ECIS (Electric cell-substrate impedance sensing) model Zθ, Applied BioPhysics Inc. (Troy, 
NY) equipment was used to monitor transendothelial electric resistance (Giaever and Keese, 
1993) of control or transfected cells seeded on type 8W10E arrays. In wound healing 
experiments an alternate current of 5 mA at 60 kHz frequency was applied for 30 sec duration 
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to establish wounds in the cell layer, and then the impedance was measured. The impedance 
in each wounded well increased gradually, until it reached a maximum plateau value. 
2.9 In vitro tube formation assay 
BD Matrigel™ Basement Membrane Matrix (BD Biosciences) was used to study the effect of 
TIMAP silencing on endothelial capillary tube formation in accordance with the 
manufacturer’s instructions. Non-silencing RNA or TIMAP-specific siRNA treated EC (~1 × 
103cells) were plated in μ-Slide (Ibidi, Germany) previously coated with Matrigel and 
incubated in triplicates at 37°C. Images at different time points of the experiment were taken 
with Leica DM IL LED microscope using N Plan 5x/0.12 objective. Quantification of 
capillary-like structures was made with Angiogenesis Analyzer ImageJ toolkit. 
2.10 Proteome Profiler™ Human Angiogenesis Antibody Array  
The Proteome Profiler Human Angiogenesis Antibody Array from R&D Systems, Inc., 
(Minneapolis, MN) was used to estimate the level of angiogenesis-related proteins in non-
silencing RNA or TIMAP-specific silencing RNA treated cell culture supernatants. Data 
analysis was done according to the recommendations in the manufacturer’s manual. Pixel 
densities of duplicated spots were measured by Image J and negative control background 
value was subtracted from the averaged signal. The experiment was repeated three times, 
therefore all single measurement was normalized against the positive controls, and then 
statistical analysis was done.  
2.11 MTT assay 
Cell viability was determined with MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium 
bromide) assay. Cells in triplicates were plated on flat-bottomed 96-well microtiter plates. At 
different time points (24, 48 ,72 h) 10µl of MTT (5 mg/ml) was added to each well, and 
incubated at 37 °C for 2h. Untransformed MTT was removed by aspiration, and the formazan 
product was dissolved in DMSO. After vigorous shake of plates the absorbance was measured 
at wavelength of 540 nm.  
2.12 Statistical analysis  
All experiments were repeated at least three times independently. Data are presented as mean 
± SE.  Statistical comparisons between groups were performed using Student’s t-test or 
Page 8 of 26
Ac
ce
pte
d M
an
us
cri
pt
ANOVA. Significant changes are indicated by asterisks; * (P<0.05), ** (P<0.01), or *** 
(P<0.001).   
3. Results 
3.1 Depletion of TIMAP induces morphological change, but does not affect viability and 
proliferation of endothelial cells 
TIMAP depletion was established in HPAEC and BPAEC by siRNA mediated silencing. The 
efficiency of silencing was confirmed by Western blot. About 70-80% decrease in the protein 
level of TIMAP was detected in the depleted cells compared to the control or non-silencing 
RNA transfected cells (Fig.1A). To test whether loss of the protein affects cell viability, MTT 
assay was performed at 24, 48 and 72 h with non-specific or TIMAP-specific siRNA treated 
cells seeded onto 96–well plates as described in Materials and Methods. The depletion of the 
protein had no significant effect on EC viability (Fig.1B). Cell proliferation was studied by 
ECIS measurements starting from a sub-confluent cell number seeded onto 8W10E array 48 h 
post-treatment, and the impedance being followed in time. During the 24 h of the experiment, 
no significant difference was observed in their proliferation (Fig.1C).   
On the other hand, silencing of TIMAP induced morphological changes in EC shown both by 
light microscopy and by immunofluorescent staining using TO-PRO Iodide as nuclear marker 
and CD31 as membrane marker (Fig.1D). In the absence of TIMAP, the morphology of the 
cells appeared as in shear stress-induced aligned state, resembling an angiogenic phenotype.  
3.2 Silencing of TIMAP accelerates tube formation and migration of EC 
To investigate the potential role of TIMAP in angiogenesis, first we examined the effect of 
TIMAP depletion on endothelial tube formation in vitro. The assay measures the ability of EC 
to form capillary-like structures, “tubes” in Matrigel extracellular matrix. Non-siRNA or 
TIMAP-specific siRNA treated cells were used 48 h post-transfection. The behavior of the 
cells during the tube formation process was analyzed (Fig.2). The depleted cells showed faster 
dynamics of tube formation as they already aligned end-to-end 2 h after plating on Matrigel 
and started to form capillary like structures earlier than the non-siRNA treated cells. Images 
taken during the experiment were evaluated by measuring the number of junctions and total 
length of the tubes as indexes of angiogenesis. As shown in Fig.2, TIMAP depletion greatly 
accelerated the formation of tube-like structures. Both total length of tubes and number of 
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junctions were significantly increased in TIMAP-specific siRNA treated cells up to 5 h after 
seeding, but the differences have disappeared at the longer time-points of the experiment.  
The migration of cells was assessed by in vitro wound healing assay carried out by ECIS 
measurements. Cells were grown until forming a confluent monolayer on ECIS arrays, and 
then an alternate current was applied to establish wounds in the cell layer, which led to the 
death of cells in a well-defined area. The impedance was monitored to chart the migration of 
EC from nearby and the ultimate healing of the wound. We did not find any difference in the 
proliferations of non-siRNA treated or TIMAP depleted EC (Fig.1c), therefore variations 
detected during the wound healing assay reflect variation in cell migration. The in vitro 
wound healing assay showed that knockdown of TIMAP expression increases EC migration, 
as evidenced by the increased speed of wound closure (Fig.3).  
Together, these data suggest that TIMAP depletion promotes angiogenesis without promoting 
cell proliferation. Since TIMAP was identified earlier as a regulatory/targeting subunit of 
PP1cβ, one can assume that phosphorylation level of an angiogenesis-related protein can not 
be modulated by the TIMAP-PP1c complex in the absence of TIMAP. 
3.3 Secretion of ET-1 is regulated by TIMAP 
A human cytokine array including 55 different angiogenesis-related proteins was used to 
further screen the effect of TIMAP depletion. In our experiments we used cell culture 
supernates of nonsiRNA and siTIMAP RNA treated cells, and shown are the results for the 13 
strongest positive hits,  and we found that the level of ET-1 was elevated due to the TIMAP 
depletion (Fig.4). EC express ETB type endothelin receptor, therefore, a specific ETB receptor 
antagonist, BQ788 (Ishikawa t al., 1994, Hersch et al., 2004, Okada and Nishikibe, 2002), 
was employed to test whether the changes observed in TIMAP-depleted EC are actually 
evoked by the elevated ET-1 secretion.  Cells were treated with 1µM BQ788 in the last 24 h 
of silencing and their morphology was studied by immunofluorescent staining. BQ788 
diminished the effect of TIMAP depletion, as the antagonist treated cells showed no 
significant difference in their morphology compared to non-siRNA treated cells (Fig.5A).  
To verify the role of the elevated ET-1 level in the tube formation process, in vitro tube 
formation assays with non-siRNA and TIMAP-specific siRNA treated cells were made in the 
presence or absence of BQ788. The tube formation ability of the cells was compared at 5 h 
after seeding on Matrigel, since the biggest difference was found at this time point in the 
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previous experiment (see Fig.2). Again, treatment of the cells with the ETB receptor 
antagonist diminished the effect of the TIMAP depletion (Fig.5B). Pretreatment with receptor 
antagonist for 30 min and then performing an in vitro wound healing assay revealed that 
BQ788 decreased the wound healing ability of the cells, furthermore, there was no difference 
in the wound healing of the non-siRNA treated or TIMAP-depleted cells in the presence of 
BQ788 (Fig.5C).   
These results imply a connection between the elevated level of ET-1 and the change in 
morphology, the faster tube formation and wound healing/cell migration of TIMAP-silenced 
EC suggesting that TIMAP/TIMAP-PP1c may play an essential role in affecting the 
properties of EC through a regulation of ET-1 secretion. 
3.4 TIMAP-PP1c is involved in the membrane localization of ECE-1 
The generation of ET-1 is crucially dependent on the local presence and activity of ECE-1 on 
the surface of vascular EC (Kuruppu and Smith, 2012). PKC phosphorylates ECE-1c and the 
phosphorylated form translocates to the plasma membrane (Kuruppu et al., 2010). As a 
potential phospho-target of PP1, first we tested and confirmed a protein-protein interaction 
between TIMAP, PP1c and ECE-1 in EC by immunoprecipitation (Fig.6A). Next, the effect 
of TIMAP depletion on the localization of ECE-1 was studied in membrane fractions of the 
non-siRNA or TIMAP-specific siRNA treate  cells. Although there was no significant change 
in the ECE-1 level in total cell lysates, about 2-3fold increase of the ECE-1 protein was 
detected in the membrane fraction of TIMAP-depleted cells (Fig.6B). This result suggests an 
alteration in the kinase to phosphatase activity ratio in the silenced EC. 
To change the phosphorylation level of ECE-1 by shifting the kinase-phosphatase equilibrium 
in non-depleted EC, PMA treatment was utilized to activate PKC and initiate phosphorylation 
and translocation of ECE-1 to the cell membrane (Fig.7), or Gö6983 pre-treatment , specific 
inhibitor of PKC, was used before the PMA-challenge in control experiments. PMA induced 
translocation of ECE-1, which was inhibited by the Gö6983 pre-treatment. Protein-protein 
interactions between ECE-1 and TIMAP-PP1c were proven by immunoprecipitation of either 
TIMAP or ECE-1 from the membrane fractions of PMA treated EC (Fig.7A). It is important 
to note the fixed ratio of the detected proteins although the efficiency of the two antibodies 
utilized for immunoprecipitation was different. 
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To further test whether TIMAP-PP1c is involved in the dephosphorylation of ECE-1 in EC, 
membrane fractions were isolated from cells without addition of PMA, after 10 min PMA 
treatment, and 30 minutes after removing PMA. In non-siRNA treated cells, PMA greatly 
increased the membrane presence of ECE-1, but it was reduced after 30 min suggesting 
dephosphorylation of ECE-1. However, the already elevated ECE-1 protein level in the 
membrane fraction of TIMAP-depleted cells showed no significant alteration after PMA 
challenge (Fig.7B). Finally, we showed the involvement of PP1 activity in ET-1 production 
utilizing type-specific phosphatase inhibitors. ET-1 secretion from EC treated with 1 µM 
tautomycetin, a PP1-specific inhibitor was comparable with the ET-1 production of TIMAP 
depleted cells (Fig.7C). However, specific inhibition of PP2A and PP2B phosphatases, by 
okadaic acid or cyclosporine A, respectively, did not increase ET-1 secretion at all. 
4. Discussion 
Several recent studies demonstrate the contribution of the TIMAP-PP1c complex in major 
physiological activities of EC through the regulation of phosphorylation levels of various 
proteins (Boratko et al., 2013, Czikora et al., 2011, Csortos et al., 2008, Kim et al., 2005, 
Shopik et al., 2013). PP1c can be targeted by many regulatory subunits (Cohen, 2002) and 
dephosphorylates a great number of phosphoproteins in all subcellular fractions of the cell. 
Therefore, in order to learn more about the specific role of the TIMAP-PP1c complex in EC 
without perturbing too many signaling pathways, experiments of this work aimed at TIMAP 
primarily.  
The apparent morphological change evoked by silencing of TIMAP was manifested in an 
elongated shape and alignment and in accelerated tube formation and cell migration of EC. 
Another recent study, on the contrary, has demonstrated reduced HUVEC migration due to 
PP1cβ knockdown, and the Authors claim that silencing/inhibition of PP1c activity had no 
effect on EC the tube formation (Iacobazzi et al., 2015). Knockdown of PP1cβ could affect 
several signaling pathways through different targeting of the phosphatase catalytic subunit.  
Investigation of the possible effect of TIMAP depletion on the secretion of angiogenesis 
related proteins demonstrated that in case of TIMAP-silenced cells there is about 30% 
increase in the secreted ET-1 level compared to the non-siRNA transfected EC 48 h post-
transfection. Treatment with specific ETB receptor antagonist, BQ788, demonstrated that the 
raised level of secreted ET-1 activated an autocrine signaling and was indeed responsible for 
the changes in TIMAP-depleted EC.  Another study, using a different endothelial cell line, 
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also reported ET-1 inducing angiogenic phenotype of cultured HUVEC through the ETB 
receptor (Salani et al., 2000), however, detailed mechanism was not provided.  
ET-1 is a potent vasoconstrictor and it is intimately employed in several normal and 
pathological activities of EC (Kedzierski and Yanagisawa, 2001, Grant et al., 2003, Kelly and 
Whitworth, 1999, Salani et al., 2000, Bagnato and Rosano, 2008, Tanfin et al., 2011). Role of 
ET-1 in lung diseases is recognized, for example increased circulating ET-1 is associated with 
pulmonary arterial hypertension (Fagan et al., 2001, Galie et al., 2004, Chester and Yacoub, 
2014). Myosin phosphatase (MP) plays a central role in myosin light chain dephosphorylation 
and smooth muscle cell contraction/relaxation.  MP consists of a PP1 catalytic subunit and its 
targeting subunit, MYPT1. ET-1 was shown to inhibit MP activity in smooth muscle through 
phosphorylation of MYPT1 via G protein signaling mediated by ETA (Hersch et al., 2004). 
However, connection between TIMAP-PP1c and ET-1 has not been recognized earlier. 
Production of active ET-1 depends on the metalloprotease, ECE-1. Therefore, one may 
assume that ECE-1 is the link between TIMAP depletion and elevated ET-1 secretion. The 
ECE-1 protein level studied 48 h post-transfection in total lysates of TIMAP-depleted cells 
showed no significant difference compared to the controls. Thus, it is not likely that altered 
ECE-1 protein expression would be responsible for the elevated ET-1 level in our system, 
although one earlier work done on rat EC (Naomi et al., 1998) suggested that ECE-1 mRNA 
variations may affect ET-1 production. On the other hand, we detected an increased ECE-1 
level in the membrane fraction of TIMAP-depleted EC, which rather suggests post-
translational modification and trafficking of ECE-1. 
Several isoforms (a-d) of ECE-1 are known; their catalytic domains at the C-terminal part of 
the protein are identical, but they differ in length and composition of the cytosolic N-terminal 
regions. Isoforms b-d are constitutively phosphorylated (at Ser18 and Ser20 in ECE-1c), and 
despite the differences in the primary structure of the N-terminus, they share further potential 
phosphorylation sites (Kuruppu and Smith, 2012, MacLeod et al., 2002). Importantly, it is 
well known that PKC regulates the cell surface activity of the ECE-1c isoform through its 
phosphorylation (likely additional to the constitutively phosphorylated sites) and consequent 
trafficking to the cell surface (Smith et al., 2006, Kuruppu et al., 2010). For that reason, 
although isoform specific antibody against ECE-1 is not available, our results strongly suggest 
that the isoform concerned in the presented work is ECE-1c.  
Page 13 of 26
Ac
ce
pte
d M
an
us
cri
pt
The protein phosphatase counterpart for the reversible phosphorylation of ECE-1 which 
establishes an appropriate equilibrium with PKC, however, has not been known earlier. 
Therefore, we tested the hypothesis of TIMAP-PP1c being involved in ET signaling by the 
regulation of ECE-1 dephosphorylation. First of all, our results showed protein-protein 
interaction between ECE-1 and TIMAP-PP1c. Then, shifting the kinase to phosphatase 
activity ratio either by activation of PKC by PMA treatment, or by decreasing the TIMAP-
PP1c activity via depletion of the targeting subunit, TIMAP, of the phosphatase complex, 
resulted in an elevated ECE-1 protein level in the plasma membrane fraction of EC. In non-
siRNA transfected cells not only ECE-1, but TIMAP-PP1c protein levels were also increased 
in the plasma membrane after the PMA challenge. Notably, 30 min after the removal of the 
PMA, the ECE-1 level in the membrane was significantly decreased. Conversely, when 
TIMAP-depleted EC was challenged with PMA, activation of PKC could not evoke any 
further increase in the already elevated ECE-1 protein level. These results strongly suggest 
that the protein phosphatase, which controls ECE-1 trafficking and activity at the cell 
membrane through its dephosphorylation, is the TIMAP-PP1 complex.  
5. Conclusions 
The results presented in this study show the contribution of TIMAP-PP1c holoenzyme form 
of PP1 in the regulation of ET-1 secretion/ET-1 signaling of EC via affecting the 
phosphorylation level of ECE-1. This may imply that TIMAP is involved in the regulation of 
important processes of EC such as cardiovascular homeostasis, tumorigenesis, vascular 
permeability, and angiogenesis.  
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Figure 1. Viability, proliferation and morphology of TIMAP depleted EC. (A) HPAEC cells 
were transfected with non-silencing RNA (nsRNA) or with 50 nM siPPP1R16B RNA 
(siTIMAP) as described in Materials and Methods. Efficiency of depletion was analyzed by 
Western blot of non-transfected (ctr), non-silencing RNA (nsRNA), or siPPP1R16B 
transfected cells using TIMAP-specific antibody. Actin was tested as loading control. The 
amount of TIMAP signal was expressed as ratio of TIMAP:β-actin signal density. The error 
bars correspond to SE from 3 independent transfections. Statistical analysis was done with 
Student’s t-test. Significant changes are indicated by asterisks;*** (P < 0.001). (B) Cell 
viability was measured by MTT assay as described in Materials and Methods. Cells 
transfected with non-siRNA or siTIMAP RNA were seeded onto 96–well plates and 
measurements were carried out at 24, 48 and 72 h later. Values are means ± SE. Results are 
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representative of 3 separate experiments. (C) Non-silencing or TIMAP specific silencing 
RNA transfected cells were plated (5 x 105 cells/well) onto two 8W10E arrays 48 h post-
transfection. The initial resistance values at the beginning of the measurement were about 300 
Ω and the impedance was measured for 24 h after the seeding. (D) Light microscopy images 
of nsRNA (a) or siTIMAP RNA (b) treated cells or immunofluorescent staining using CD31 
primary antibody of nsRNA (c) or siTIMAP RNA (d) treated cells 48 h post-transfection. 
Nuclei of the cells were stained using TO-PRO-3 Iodide (blue). Non-specific binding of the 
secondary antibodies was checked in control experiments (not shown). Representative data of 
at least three independent experiments are shown. Scale bars: 500 µm (a and b), 50 µm (c and 
d). 
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Figure 2. The effect of TIMAP depletion on tube formation. BPAEC cell were treated with 
non-silencing or TIMAP-specific siRNA. Cells were seeded onto Matrigel 48h post-
transfection and observed in time. Quantification of capillary formation was determined using 
the ImageJ program. Data are reported as mean ± SE. Statistical analysis was done with 
Student’s t-test. Significant changes are indicated by asterisks;** (P < 0.01). Scale bar: 200 
µm.
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Figure 3. Faster in vitro wound healing of TIMAP depleted HPAEC. Cells plated onto two 
8W10E arrays were treated with non-siRNA or siTIMAP RNA. 48 h post-transfection (about 
1000 Ω impedance) an alternate current of 5 mA at 60 kHz frequency was applied for a 30 sec 
duration to establish wounds in the cell layer, after which the impedance was measured. The 
average results from three independent experiments each made with four parallel 
measurements are shown. Error bars represent SE. 
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Figure 4. Angiogenesis protein array. Relative levels of human angiogenesis-related proteins 
were evaluated from HPAEC and BPAEC cell culture supernatants of non-siRNA or 
siTIMAP RNA- treated cells using a human angiogenesis array kit (Proteome Profiler, R&D 
Systems) according to the manufacturer’s recommendations. Shown are pixel densities of 
positive hits quantified by ImageJ. Data are reported as mean ± SE from three independent 
experiments. Statistical analysis was performed with ANOVA. Significant changes are 
indicated by asterisks;** (P < 0.01).  
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Figure 5. ETB antagonist diminishes he effects of TIMAP silencing. (A) 
Immunofluorescent staining was made using CD31 primary antibody to show the morphology 
of non-siRNA or siTIMAP RNA treated BPAEC 48 h post-transfection with or without 
BQ788 in the last 24 h of silencing. Nuclei of the cells were stained using TO-PRO-3 Iodide 
(blue). Representative pictures of at least three independent experiments are shown. Scale bar: 
50 µm. (B) Non-silencing or TIMAP-specific siRNA treated cells were seeded on Matrigel 48 
h post-transfection with or without BQ788. Quantification of capillary formation was 
determined using ImageJ at 5 h after seeding. Data are reported as mean ± SE. Statistical 
analysis was done with ANOVA. Significant changes are indicated by asterisks;** (P < 0.01). 
(C) Cells plated onto two 8W10E arrays were treated with non siRNA or siTIMAP RNA. 48 h 
post-transfection vehicle or BQ788 was added and an alternate current of 5 mA at 60 kHz 
frequency was applied for 30 sec duration to establish wounds in the cell layer; after that the 
impedance was measured. The average results from three independent experiments each made 
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with four parallel measurements are shown. Error bars represent SE.
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Figure 6. Protein-protein interaction between ECE-1 and TIMAP-PP1c. (A) TIMAP or ECE-1 
was immunoprecipitated from lysates of BPAEC as described in Materials and Methods. IP 
complexes were probed for TIMAP, ECE-1 and PP1c. (B) Membrane fractionation of non-
silencing RNA and TIMAP-specific siRNA treated BPAEC was performed as described in 
Materials and Methods. The fractions were analyzed with anti-TIMAP, anti-ECE-1 and anti-
CD31 (membrane marker) antibodies. The error bars correspond to SE from 3 independent 
experiments. Statistical analysis was done with Student’s t-test. Significant changes are 
indicated by asterisks;** (P < 0.01). Shown are representative data of at least 3 independent 
experiments. 
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Figure 7. TIMAP-PP1c regulates membrane localization of ECE-1. (A) TIMAP or ECE-1 was 
immunoprecipitated from membrane fractions of untreated, PMA (1µM, 10’) or Gö6983 
pretreated (5µM, 30’) and PMA challenged (1µM, 10 min) BPAEC cells as described in 
Materials and Methods. IP complexes were probed for TIMAP, ECE-1 and PP1c. (B) 
Membrane fractionation of nsRNA or TIMAP-specific siRNA treated BPAEC were made 
from untreated, PMA (1µM, 10 min) treated (right after the treatment or 30 min later) as 
described in Materials and Methods. The fractions were analyzed with anti-TIMAP, anti-
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ECE-1, anti-PP1c and anti-CD31 (membrane marker) antibodies. The error bars correspond to 
SE from 3 independent experiments. Statistical analysis was done with ANOVA. Significant 
changes are indicated by asterisks; *(P < 0.05),***(P < 0.001).  (C) ET-1 secretion was 
compared by dot blot from non-treated BPAEC (control) or BPAEC treated with vehicle 
(DMSO), 1 µM tautomycetin (TM), 5 nM okadaic acid (OA), or 2 µM cyclosporine A (CsA) 
for 24 h and BPAEC transfected with non-specific (nonsiRNA) or TIMAP-specific 
(siTIMAP) siRNA. Supernates’ proteins were immobilized on nitrocellulose membrane, and 
the membranes were blocked with 5% low-fat milk containing TBST, and then incubated for 
1h with ET-1 specific and another 1h with the secondary antibody. 
 Shown are representative data of at least 3 independent experiments. 
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